Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129928 | 0.85 | BRAF (0.54) | BRAFMAP3K20 | |
| SCHEMBL14317723 | 0.84 | BRAF (0.51) | BRAFRAF1MAP3K20 | |
| SCHEMBL10129575 | 0.80 | BRAF (0.51) | BRAFRAF1MAP3K20 | |
| SCHEMBL10129920 | 0.80 | BRAF (0.59) | BRAFCYP2C19CYP2C9CYP3A4MAP3K20 | |
| SCHEMBL10129954 | 0.80 | BRAF (0.56) | BRAFRAF1MAP3K20 | |
| SCHEMBL16573187 | 0.80 | BRAF (0.50) | BRAFRAF1MAP3K20 | |
| SCHEMBL14316922 | 0.79 | BRAF (0.58) | BRAFCYP2C19CYP2C9CYP3A4MAP3K20 | |
| SCHEMBL14317716 | 0.79 | BRAF (0.47) | BRAFRAF1MAP3K20 | |
| SCHEMBL10129582 | 0.78 | BRAF (0.57) | BRAFCYP2C19CYP2C9CYP3A4MAP3K20 | |
| SCHEMBL10129589 | 0.78 | BRAF (0.51) | BRAFRAF1MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655355-B1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012085127-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | CDK2, TNNI3K, CDK1 | BRAF 16/4885CYP2C19 4147/4885RAF1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.